CClinicalTrials.gg
CompletedNCT05488886Updated Mar 31, 2023

Bioavailability of Aronia Berry Polyphenols

An interventional study of Whole Aronia Berry Powder Applesauce and Aronia Berry Extract Applesauce in Gut Health, Metabolism and Polyphenols, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to conduct a randomized cross-over dietary intervention among healthy adults to compare the bioavailability and the fecal polyphenol metabolites of intervention foods made with whole aronia berry powder, aronia berry extract, phospholipid-polyphenol (PLP), and a low-polyphenol control. 10 participants will be enrolled and can expect to be on study for up to 28 days.

Read the detailed description

Inflammatory bowel diseases (IBD): Crohn's disease and ulcerative colitis are two conditions of IBD that are characterized by chronic inflammation and damage of the gastrointestinal tract. In the United States alone, IBD are estimated to affect as many as 1.6 million people. IBD are associated with high morbidity, decreased quality of life, as well as substantial health care costs. IBD currently have no known cure, and treatment of IBD often requires the use of potent immunosuppressors which may lead to side effects or surgery.

Berries and prevention of chronic inflammation: Anthocyanins and other polyphenols are promising dietary agents to prevent and treat IBD by improving intestinal barrier dysfunction, inhibiting differentiation of pro-inflammatory T cells, reducing production of proinflammatory cytokines, and preventing oxidative stress. While preliminary studies are promising, translational human intervention studies are needed to refine delivery of polyphenol-rich foods and to confirm anti-inflammatory mechanisms.

Berries are rich dietary sources of polyphenols and essential nutrients. Polyphenol intake varies significantly by dietary patterns, but mean intake is estimated \~900 mg/day. Among berries, the polyphenol-dense aronia berry is one of the richest sources of fruit polyphenols.

Challenges associated with aronia berry consumption: In spite of its beneficial nutritional properties, the consumption of large amounts of whole aronia berry is not practical because of significant sorbitol and fiber content, which could lead to gastrointestinal discomfort for some individuals. Particularly, IBD patients often are required to limit fiber and whole fruit intake. The investigator's research group recently developed a novel method to extract polyphenols from fruit juice using food-grade lecithin which overcomes this problem.

The investigators hypothesize the resulting phospholipid-polyphenol (PLP) enriched material can improve the delivery of anthocyanins to the gut relative to a purified extract, and similar to that of whole berry. The aim of this study is to determine the comparative metabolism and bioavailability of aronia berry PLP intervention to extract, whole berry, and control food.

Consumption of Intervention Foods: In the morning of the day of each intervention and sampling period (days 6, 13, 20, and 27 i), participants will be asked to visit the Bolling Laboratory at the Department of Food Science fasted. Participants will then be asked to empty their bladders and then consume one serving of the applesauce (≤200 g). Then, in the next 24 h, participants will be asked to only consume commercially available frozen and shelf-stable low-polyphenol meals and snacks provided by study personnel. Insulated bags will be provided to participants for transport of frozen meals. The low-polyphenol diet and snacks will consist of dairy products, meat, low-phenolic snacks (e.g., banana, potato chips) and starch sources (e.g. white bread, rice, and plain bagels). Water will be available to participants over the time course, and its intake is not restricted.

02

Conditions studied

  • Gut Health
  • Metabolism
  • Polyphenols
03

In context

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,161 studies on the registry; 182 are open to participants now.

Of its 151 completed or terminated interventional studies of FDA-regulated products, 114 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • willing to consume low-anthocyanin diets during the last days of wash-in and wash-out periods
  • willing to consume intervention foods during the sampling periods
  • willing to provide 24-hour urine and fecal samples during the sampling periods.

Exclusion criteria

Exclusion Criteria:

  • people who do not consider themselves healthy
  • anyone with a self-reported previous diagnosis of a gastrointestinal disease (e.g. inflammatory bowel disease, irritable bowel syndrome)
  • undergoing current cancer treatment (i.e., chemotherapy, radiation therapy)
  • are pregnant, lactating, or trying to become pregnant
  • unwilling to consume study foods, or are allergic to sunflower, food colorants, berry ingredients, or any other component of the study foods.
  • taking medication that contraindicates grapefruit juice consumption
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    A: Whole Aronia Berry Powder

    Dietary Supplement: Whole Aronia Berry Powder Applesauce

  • Experimental
    B: Aronia Berry Extract

    Dietary Supplement: Aronia Berry Extract Applesauce

  • Experimental
    C: Phospholipid-Polyphenol

    Dietary Supplement: Phospholipid-Polyphenol Applesauce

  • Experimental
    D: Low-Polyphenol Control

    Other: Low-Polyphenol Control Applesauce

Interventions

  • Dietary supplementWhole Aronia Berry Powder Applesauce

    The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).

  • Dietary supplementAronia Berry Extract Applesauce

    The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).

  • Dietary supplementPhospholipid-Polyphenol Applesauce

    The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).

  • OtherLow-Polyphenol Control Applesauce

    The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.

06

What researchers measure

Primary outcomes

  1. Urinary Polyphenol Catabolite Concentration

    Targeted analysis of free urinary polyphenol metabolites will be performed by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS).

    Time frame: sampled on day 6, 13, 20, and 27 (participant randomized to different interventions each visit)

  2. Urinary Anthocyanin Concentration

    C18 solid-phase extraction (SPE) clean-up methods will be used to isolate anthocyanins and non-anthocyanin low-molecular weight polyphenol metabolites.

    Time frame: sampled on day 6, 13, 20, and 27 (participant randomized to different interventions each visit)

  3. Fecal Polyphenol Catabolite Concentration

    C18 solid-phase extraction (SPE) clean-up methods will be used to isolate anthocyanins and non-anthocyanin low-molecular weight polyphenol metabolites.

    Time frame: sampled on day 6, 13, 20, and 27 (participant randomized to different interventions each visit)

  4. Fecal Anthocyanin Concentration

    C18 solid-phase extraction (SPE) clean-up methods will be used to isolate anthocyanins and non-anthocyanin low-molecular weight polyphenol metabolites.

    Time frame: sampled on day 6, 13, 20, and 27 (participant randomized to different interventions each visit)

  5. Urine Creatinine Content

    The urine creatinine content will be measured by a urinary creatinine colorimetric assay kit (Cayman Chemical).

    Time frame: sampled on day 6, 13, 20, and 27 (participant randomized to different interventions each visit)

07

Study locations

1 site
  • University of Wisconsin
    Madison, Wisconsin 53706, United States
08

References and documents

Study documents

  • Informed consent form · Jan 23, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05488886
Lead sponsor
University of Wisconsin, Madison
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Feb 9, 2023
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Last update
Mar 31, 2023

Study contacts

Bradley Bolling, PhD
principal investigator · University of Wisconsin, Madison

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion